Journal Papers

2016:

M.J. Firth, K. J. Sharples, V. A. Hinder, J. Macapagal, D. Sarfati, S. L. Derrett, A. G. Hill, C. Brown, P. M. J. Reid, R. A. Lawrenson, C. Atmore, J. P. Keating, M. Jeffery, A. H. Secker, C. De Groot, C. G. C. A. JacksonM. P. N. Findlay. Methods of a national colorectal cancer cohort study: the PIPER Project. New Zealand Medical Journal. Volume 129 Number 1440: 19 August 2016.

K.E. Burns, W-Y. Lo, M.P. Findlay, K. Sharples, G. Laking, N.A. Helsby. High CYP2C19 phenotypic variability in gastrointestinal cancer patients. Cancer Chemotherapy & Pharmacology. 77(1):195-204, 2016

G van Hazel, V. Heinemann, N. Sharma, M. Findlayet. al. SIRFLOX: Randomised phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. Journal of Clinical Oncology. Published online before print February 22, 2016 doi: 10.1200/JCO.2015.66.1181.

2015:

Burns KE, Lo W-Y, Findlay MPSharples K, Laking G, Helsby NA. High CYP2C19 phenotypic variability in gastrointestinal cancer patients. Cancer Chemotherapy and Pharmacology. 2015 Nov 27. [Epub ahead of print].

D Perez, K. Sharples, R. Broom, M. Jeffery, J. ProctorV. HinderS. Pollard, J. Edwards, A. Simpson, J. ScottS. Benge, G. Krissansen, A. Geursen, K. Palmano, A. MacGibbon, D. Keefe, M. Findlay. A randomised phase IIb trial to assess the efficacy of ReCharge ice-cream in preventing chemotherapy-induced diarrhoea. Support Care Cancer. 2015 Nov; 23(11):3307-15.

Lawrence N, Hinder VMurray MMacapagal J, Thompson P, Sharples KFindlay M. Transient elevation in serum carcinoembryonic antigen while on adjuvant chemotherapy for colon cancer: Is this of prognostic importance? Asia-Pacific Journal of Clinical Oncology. 2015 Aug 6. doi: 10.1111/ajco.12402

Broom RJ, Hinder VSharples KProctor JDuffey SPollard S, Fong PCC, Forgeson G, Harris DL, Jameson MB, O’Donnell A, North RT, Deva S, Hanning FJ, Grey A, Findlay MPN. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: A randomized first-line phase II trial. Clinical Genitourinary Cancer. 2015 Feb; 13(1): 50-58.

Hunn MK, Bauer E, Wood CE, Gasser O, Dzhelali M, Ancelet LR, Mester B, Sharples KJFindlay MP, Hamilton DA, Hermans IF. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. Journal of Neuro-Oncology. 2015 Jan; 121(2): 319-329.

Prasad N, Sharples KJ, Murdoch DR, Crump J.A. Community prevalence of fever and relationship with malaria among infants and children in low-resource areas. Am J of Tropical Medicine and Hygiene. 93 (1) (pp 178-180), 2015.

Jackson CGCA, Sharples K, Murray M, Hinder V, Jeffrey M, Keating J, Secker A, Derrett S, Atmore C, Bramley D, De Groot C, Stevens W, Sarfati S, Brown C, Hill A, Reid P, Lawrenson R, Findlay MP. The PIPER Project: and internal examination of colorectal cancer management in New Zealand. Final report for the Health Research Council and the Ministry of Health, 7th April 2015. Available online https://www.fmhs.auckland.ac.nz/en/sms/about/our-departments/oncology/cancer-trials-nz/trials-and-research-projects/open/piper-project.html. Updated 2015. Accessed December 3, 2015.

Stairmand J, Signal L, Sarfati D, Jackson C, Batten L, Holdaway M, Cunningham C. Consideration of comorbidity in treatment decision-making in multidisciplinary cancer team meetings: a systematic review. Ann Oncol. 2015 Jan 20 pii: mdv025.

Wilson MK, Karakasis K, Oza AM: Discrepancies in drug approvals: A global dilemma. Cancer 121:3360-1, 2015

Wilson MK, Fong P, Mesnage S, et al: Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up. Gynecol Oncol 138:285-91, 2015

Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, Biagi JJ, Reedijk M, Weberpals JI, Fleming GF, Wang L, Liu G, Zhou C, Blattler C, Ivy SP, Oza AM. A phase II study of singleagent RO4929097, a gammasecretase inhibitor of Notch signalling, in patients with recurrent platinumresistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol. 2015 May; 137(2):216-22

Wilson MK, Karakasis K, Oza A. Outcomes and endpoints in cancer trials – the past, present and future (Part 1 of 2).  The Lancet Oncology 2015; 16 (1):e32-42

Wilson MK, Collier D, Chingos D, Kaye S, Friedlander M, Sydes M, Parmar M, Karakasis K, Tannock I, Oza A. Outcomes and endpoints in cancer trials – bridging the divide (Part 2 of 2). The Lancet Oncology 2015; 16 (1):e43-52

Castonguay V, Wilson MK, Diaz-Padilla I, Wang L, Oza A. Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomised phase 3 studies in epithelial ovarian cancer.  Cancer. 2015; 121(3):41322

2014:

Jackson ChristopherSharples Katrina, Thompson I Paul, O’Donnell  Anne, Robinson Anne Bridget, Perez J David, Adams  Jacqui, Isaacs  Richard, Deva  Sanjeev, Hinder A Victoria, Findlay Michael.  Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. BMC Cancer. 2014, 14:737 DOI: 10.1186/1471-2407-14-737

Broom, R. J., Hinder, V, ..Findlay, M.P., Clinical Genitourinary Cancer (2014). Everolimus and zoledronic acid in renal cell carcinoma patients with bone metastases; a randomized first-line phase II Trial

Tiong J1, Gray A, Jackson C, Thompson-Fawcett M, Schultz M. Audit of the association between length of time spent on diagnostic work-up and tumour stage in patients with symptomatic colon cancer. ANZ J Surg. 2014 Aug 4. doi: 10.1111/ans.12804.

Jackson C, Ehrenberg N, Frizelle F, Sarfati D, Balasingam A, Pearse M, Parry S, Print C, Findlay M, Bissett I. Rectal cancer: future directions and priorities for treatment, research and policy in New Zealand. N Z Med J. 2014 Jun 6;127(1395):63-72.

Jackson C, Robinson B, Findlay M. Cancer services to 2025 in New Zealand–investing in research-driven quality care. N Z Med J. 2014 Jun 6;127(1395):5-9.

Lheureux S, Wilson MK, Sinaei M, O’Malley M, Oza A. Non-target progression – the fine line between objectivity and subjectivity.  European Journal of Cancer 2014; 50 (18):3271-2.

Lheureux S, Wilson MK, Mackay HJ. Recent and current Phase II clinical trials in endometrial cancer: review of the state of the art. Expert Opin Investig Drugs. 2014; 23 (6): 773-92

Wilson MK, Baguley B, Wall C, Jameson M, Findlay M. Review of high dose intravenous vitamin C in cancer therapy. Asia Pacific journal of clinical oncology. 2014; 10(1): 22-37

Plunkett M, Murray M,  Frizelle F, Teague L, Hinder VFindlay M. Colorectal Adenocarcinoma Cancer in New Zealand in those under 25 years of age (1997-2007). The ANZ Journal of Surgery. 84(5): 371-375, 2014.

2013:

Jackson C, McCall J, Robinson B, Sharples KFindlay M. Cancer trials in New Zealand—patients are not the problem (Editorial). NZMJ 30 Aug 2013. Vol 126 No 1381 http://journal.nzma.org.nz/journal/126-1381/5805/

Moorcraft SY, Chau I, Peckitt C, Cunningham D, Rao S, Yim KL, Walther A, Jackson C, Stamp G, Webb J, Smith G, Gillbanks A, Swanton C. Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial. Investigational New Drugs. June 2013 Epub ahead of print

Pullar JM, Chisholm A, Jackson C. Dietary information for colorectal cancer survivors: an unmet need. NZMJ 8 June 2012, Vol 125 No 1356; http://journal.nzma.org.nz/journal/125-1356/5215/

Bidwell S, Simpson A, Sullivan R, Robinson B, Thomas W, Jackson C, Forgeson G, Jameson M, Clarke T. A workforce survey of New Zealand medical oncologists. NZMJ 15 Mar 2013, Vol 126 No 1371; http://journal.nzma.org.nz/journal/126-1371/5575/

Rosario R, Wilson MK, Cheng WT, Payne K, Cohen PA, Fong P, Shelling AN. Adult granulosa cell tumours (GCT): clinicopathological outcomes including FOXL2 mutational status and expression. Gynecol Oncol. 2013 Nov; 131(2):325-9.

Walton L, McNeill R, Stevens W, Murray M, Lewis C, Aitken D, Garrett J. Patient perceptions of barriers to the early diagnosis of lung cancer and advice for health service improvement. Family Practice.  30 (4): 436-444, 2013

Plunkett, M., Murray, M., Frizelle, F., Teague, L., Hinder, V., & Findlay, M. (2013). Colorectal adenocarcinoma cancer in New Zealand in those under 25 years of age (1997-2007). ANZ J Surg. doi:10.1111/ans.12380

Harvey, V. J., Sharples, K. J., Isaacs, R. J., Jameson, M. B., Jeffery, G. M., McLaren, B. R., ..,Hinder, V.A. Scott, J.N., Dzhelali, M.V., Findlay, M. P. (2013). A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II. Ann Oncol24 (7), 1828-1834. doi:10.1093/annonc/mdt065

2012:

Cha R, Murray M, Thompson J, Wall C R, Hill A, Hulme-Moir M, Merrie A, Findlay M. Dietary patterns and information needs of colorectal cancer patients post-surgery in Auckland. The New Zealand Medical Journal 125 (1356), 2012.

O’Sullivan, P., Sharples, K., Dalphin, M., Davidson, P., Gilling, P., Cambridge, L., … Guilford, P. J. (2012). A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. The Journal of Urology188 (3), 741-747. doi:10.1016/j.juro.2012.05.003

2011:

Murray M, Brown J, Hinder V, Merrie A, Hill A, Hulme-Moir M, Sharples K, Findlay M. The Colorectal cancer patients’ journey: the Auckland region. New Zealand Medical Journal. Vol 124 No 1331. 25 March 2011.

Al-Mahrouqi H, Parkin L, Sharples K. Incidence of Stomach Cancer in Oman and the Other Gulf Cooperation Council Countries. Oman Med J 2011 Jul; 26(4):258-262.

2010:

Hill A, Bergin P, Hanning F, Thompson P, Findlay M, Damianovich D, McKeage MJ. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer 10:451  2010

Han CH, Findlay MP. Chemotherapy-induced reversible posterior leucoencephalopathy syndrome. Intern Med J 40(2):153-159  2010

Leung E, Kannan N, Krissansen GW, Findlay MP, Baguley BC. MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phosphor-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biology and Therapy 9(9):716-723  2010

Corter A, Findlay MP, Broom R, Porter D, Petrie KJ. Breast Cancer, Illness Perceptions and Non-adherence to Aromatase Inhibitors. Int J Behav Med 17:5  2010

Lawrence Ben, Findlay Michael. Systemic therapy for metastatic pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology. 2(2): 85-106. 2010.

Dare T, Findlay M, Browett P et al. Paternalism in practice: informing patients about expensive unsubsidised drugs. J Med Ethics. 260-264. 2010.

Stevens W, Murray M. Barriers to the early diagnosis of lung cancer and recommended best practice solutions, with particular reference to Maori and Pacific peoples. Australasian Epidemiologist 17.3: 11-15, 2010.

Jackson C, Sirohi B, Cunningham D et al. Lymphocyte-predominant Hodgkin lymphoma–clinical features and treatment outcomes from a 30-year experience. Ann Oncol. 2010 Oct; 21(10):2061-2068

2009:

Jackson C. Cunningham D. Oliveira J.  Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009 May;20 Suppl 4:34-6

2008:

Nowak Anna K, Cebon Jonathan, Hargreaves Carol, Dhillon H, Findlay M, Gebski V, Stockler Martin R. Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology 4:55-67  2008

Ip Virginia, McKeage Mark J, Thompson, P, Damianovich D, Findlay M, Liu Johnson J. Platinum-specific detection and quantification of oxaliplatin and Pt (R,R-diaminocyclohexane) C12 in the blood plasma of colorectal cancer patients. Journal of Analytical Atomic Spectrometry 23(6):881-884  2008

Helsby NA, Lo W-Y, Sharples K, Riley GMurray M, Spells K, Dzhelali M, Simpson A, Findlay M. CYP2C10 pharmacogenetics in advanced cancer: compromised function independent of genotype. British Journal of Cancer 99(8):1251-1255  2008

Jackson C, Cunningham D. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer. Eur J Cancer. 2008 Mar;44(5):652-62. Review

Kong G, Jackson C, Koh DM, Lewington V, Sharma B, Brown G, Cunningham D, Cook GJ. The use of (18)F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI.Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1323-9. Epub 2008 Mar 18.

Furneaux CE. Marshall ES. Yeoh K. Monteith SJ. Mews PJ. Sansur CA. Oskouian RJ. Sharples KJ. Baguley BC. Cell cycle times of short-term cultures of brain cancers as predictors of survival. British Journal of Cancer. 99(10):1678-83, 2008.

Fleming TR, Sharples K, McCall J, Moore A, Rodgers A, Stewart R. Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clinical Trials; 5: 157-167 2008.

2007:

Findlay M, Storey D, Gebski V, Hargreaves C, Cullingford G, Boyer M, Trotter J, Archer S, Davidson A, Johnston P, Yuen J, Dhillon H, Della-Fiorentina S, Richardson G, Truskett P, Goldstein D, AGITG. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601. ANZ Journal of Surgery. 77(4):247-252  2007

Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer : results from NSABP C-07. Journal of Clinical Oncology 25(16):2198-2204  2007

Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Annals of Oncology 19(2):212-222  2007

Findlay MSharples K, Riley G, Simpson A, Ackland S, Hall K, Isaacs R, Humm G, McKeage MJ. Capecitabine and oral cyclophosphamide: A novel oral treatment combination for advanced cancer. Asia-Pacific Journal of Clinical Oncology 3(2):99-105  2007

Parry S, Richardson A, Green T, Marshall B, Bissett I, Bloomfield A, Chadwick V, Cunningham C, Findlay M, Greer B, McMenamin J, Strid J, Robertson G, Teague C. Prospects for population colorectal cancer screening in New Zealand. New Zealand Medical Journal 120(1258):U2633  2007

Jackson C, Cunningham D. A Retrospective on Inhibition of EGFR as a Therapeutic Strategy for Patients with Relapsed Metastatic Colorectal Cancer: Impact on Treatment of Today’s Patients. Clin Colorectal Cancer. 2007 Dec;7 Suppl 1:S8-15

Jackson C, Starling N, Chau Y, Cunningham D. Pharmacotherapy in Oesophagogastric Cancer. Drugs. 67 (17) 2539-2556.November 2007

Jackson C, Mochlinski K, Cunningham D. Defining Standard of Care and Recognizing Adjuvant Therapeutic Options in Gastric Cancer: Neo-adjuvant Chemotherapy vs. Post-operative Chemoradiotherapy. Oncology 2007 August. 21(9): 1084-1087

Jackson C. The development of epidermal growth factor receptor-targeted therapies in gastrointestinal malignancies. Advances in Gastrointestinal Cancer. June 2007.

2006:

Sullivan RN, Findlay MPN, Zalcberg J. Adjuvant and neoadjuvant therapy for gastric carcinoma: An evidence-based review. American Journal of Cancer 5(2):111-121  2006

Blair V, Martin I, Shaw D, Winship I, Kerr D, Arnold J, Harawira P, McLeod M, Parry S, Charlton A, Findlay M, Cox B, Humar B, More H, Guilford P.  Hereditary diffuse gastric cancer: diagnosis and management. Journal of Gastroenterology & Hepatology. 4(3):262-275  2006

Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Scott AM, Kalff V, Garas G, Dowling A, Crawford D, Ring J, Basser R, Strickland A, Macdonald G, Green M, Nowak A, Dickman B, Dhillon H, Gebski V; Australasian Gastro-Intestinal Trials Group (AGITG) AG0001H Investigators. Somatostatin receptor expression, tumour response and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. (AGITG) AG0001 H Investigators. British Journal of Cancer. 95(7):853-861  2006

Dunbar R, Findlay M, Stevens G. Melanoma control: few answers, many questions. New Zealand Medical Journal. 119(1242):U2172  2006

2005:

Loi S, Findlay M, Zalcberg J. Evidence-based review of resectable pancreatic adenocarcinoma. American J Cancer 4(3):159-168. 2005

Nowak AK. Stockler MR. Chow PK. Findlay M. Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review. Journal Article. Meta-Analysis. Review] Cancer 103(7):1408-1414  2005

2004:

Damjanovic D, Thompson P, Findlay M. Evidence-based update of chemotherapy options for metastatic colorectal cancer. ANZ Journal of Surgery 74:781-787  2004

Liu J, Kestell P, Findlay MRiley G, Ackland S, Simpson A, Isaacs R, McKeage MJ. Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients. Clinical and Experimental Pharmacology and Physiology 31(10):677-682  2004

Christmas T, Findlay M. Lung cancer treatment in New Zealand: physician’s attitudes. New Zealand Medical Journal 117(1196):U931  2004

Nowak A. Findlay M. Culjak G. Stockler M. Tamoxifen for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 3  2004

Koea J, MacCormack M, Findlay M, Ramsdorp R. Adeno-endocrine cancer of the gallbladder. ANZ Journal of Surgery. 74(9):808-9  2004

Anna K Nowak, Pierce K.H Chow, M Findlay. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004. 40(10):1474-84